B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Rivoceranib

0 PubMed studies analyzed

Similar Compounds by Shared Targets

The following compounds share molecular targets with Rivoceranib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

osi
3 shared targets
poziotinib
2 shared targets
sapitinib
2 shared targets
gw305074x
2 shared targets
vatalanib
2 shared targets
regorafenib
3 shared targets
bafetinib
3 shared targets
encorafenib
2 shared targets
cep
3 shared targets
golvatinib
3 shared targets
Loading evidence profile...

This evidence profile for Rivoceranib is generated deterministically from 0 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.